OSE’s UC therapy prompts 16% clinical remission after ten weeks

OSE’s UC therapy prompts 16% clinical remission after ten weeks

Submitted by admin on February 24, 2025 - 10:17am
Source: 
Clinical Trials Arena
News Tags: 
OSE Therapeutics
lusvertikimab
clinical trials
ulcerative colitis
Headline: 
OSE’s UC therapy prompts 16% clinical remission after ten weeks
snippet: 

France-based OSE Immunotherapeutics’ (OSE) Phase II CoTikiS study of lusvertikimab has met primary and secondary endpoints, showing high rates of clinical and endoscopic remission after ten weeks in patients with ulcerative colitis (UC).

Do Not Allow Advertisers to Use My Personal information